Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is a clinical-stage oncology therapeutics company developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. The DRTS news feed highlights the company’s clinical progress, regulatory interactions, manufacturing milestones, and financial updates related to this technology.
Recent news has focused on Alpha Tau’s expanding clinical program. The company has reported final results from a first-in-human pancreatic ductal adenocarcinoma study in Montreal, including disease control and response rates, and is running the IMPACT multi-center pilot trial in the United States combining Alpha DaRT with chemotherapy in newly diagnosed unresectable or metastatic pancreatic cancer. News items also cover pilot studies in recurrent glioblastoma multiforme, including the first reported Alpha DaRT treatment in the brain, as well as FDA-approved trials in locally recurrent prostate cancer.
Regulatory and pre-market developments are another frequent theme. Alpha Tau has announced submission of the first module of its pre-market approval application to the U.S. FDA for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, under a modular PMA framework. The company also reports on Breakthrough Device Designations, participation in the FDA’s Total Product Life Cycle Advisory Program, and marketing authorization processes in other regions.
Operational and corporate updates appear regularly, including receipt of a radioactive material license for the company’s manufacturing facility in New Hampshire, participation in major healthcare and investor conferences, and periodic financial results with corporate commentary. Investors and observers can use the DRTS news page to follow key milestones in Alpha Tau’s efforts to advance Alpha DaRT through clinical development, regulatory review, and preparation for potential commercialization.
Alpha Tau (Nasdaq: DRTS) announced acceptance of the first-ever oral presentation of Alpha DaRT pancreatic cancer clinical results at Digestive Disease Week (DDW) 2026.
The abstract, “Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,” will be presented May 2, 2026 at 10:30am Central by Dr. Harold Jacob, using combined data from two Hadassah Medical Center protocols. According to the company, these foundational studies informed the IMPACT pilot now enrolling in the U.S. and ongoing planning toward a future pivotal study.
Alpha Tau (Nasdaq: DRTS) announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18, 2026 from 10:00–10:30 AM ET. The presentation is virtual and Mr. Levy is available for one‑on‑one investor meetings scheduled through Sidoti representatives.
Alpha Tau (NASDAQ: DRTS) reported full-year 2025 results and a corporate update highlighting regulatory, clinical and manufacturing progress. Key items: $76.9M cash, Japanese marketing approval for head and neck cancer, five parallel U.S. trial approvals, positive pancreatic data (ORR 22%/DCR 81%), and a commercial-scale New Hampshire license.
The company reported a $42.6M net loss for 2025 and outlined upcoming recruitment and safety readouts through 2026.
Alpha Tau Medical (Nasdaq: DRTS) received Shonin (MHLW) marketing approval in Japan for Alpha DaRT to treat unresectable locally advanced or locally recurrent head and neck cancer on Feb 24, 2026.
The approval is the platform's first regulatory clearance outside Israel and requires a post-market surveillance study enrolling 66 patients across five Japanese centers. The company plans discussions on reimbursement and further clinical evaluation with Japanese regulators and clinicians.
Alpha Tau (Nasdaq: DRTS) outlined a busy 2026 with five concurrent U.S. clinical trials, targeted patient‑accrual milestones and planned data readouts across pancreatic cancer, GBM and recurrent cutaneous SCC.
The company reported FDA Modular PMA submissions, a radioactive license for its Hudson, NH manufacturing phase, ongoing manufacturing scale‑up, and extensive IP activity (60+ filings, ~50 grants).
Alpha Tau (Nasdaq: DRTS) reported final results from its first-in-human pancreatic ductal adenocarcinoma (PDAC) study in Montreal, with data presented at ASCO GI 2026 (Jan 8–10, 2026).
Key clinical readouts: 22% objective response rate (ORR) and 81% disease control rate (DCR) across 32 patients (or 23% ORR and 87% DCR excluding the first two low‑dose patients). Immune marker analysis in 23 patients showed no significant worsening of NLR, PLR, CD4/CD8 ratio, or CRP one month post‑treatment, plus a dramatic drop in IL‑6 (p<0.000001), suggesting immune preservation and a potential anti‑inflammatory effect. The company is continuing U.S. multi‑center combination testing in the IMPACT trial (NCT06698458).
Alpha Tau (NASDAQ: DRTS) submitted the first module of a PMA application to the FDA on Jan 5, 2026, using a modular submission approach allowed by the FDA to enable ongoing review and feedback.
The submitted module focuses on non-clinical study documentation for Alpha DaRT® to treat recurrent cutaneous squamous cell carcinoma (cSCC) in patients not eligible for surgery or standard radiation.
Alpha Tau is running the multi-center pivotal ReSTART study, expects to complete patient recruitment in Q1 2026, and holds Breakthrough Device Designation for recurrent cSCC, recurrent GBM, and recurrent oral cavity SCC.
Alpha Tau (NASDAQ: DRTS) will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 11:15am PT / 2:15pm ET in San Francisco.
CEO Uzi Sofer and CFO Raphi Levy will review recent achievements and the outlook for upcoming data milestones, and will host institutional 1-on-1 investor meetings. The presentation runs 11:15am–11:55am PT at Westin St. Francis. A webcast link will be posted on the company’s Events & Presentations page.
Alpha Tau (Nasdaq: DRTS) announced on December 9, 2025 that it treated the first patient in a U.S. pilot study of Alpha DaRT for recurrent glioblastoma multiforme (GBM) at The Ohio State University James Cancer Hospital.
The procedure used a novel intracranial delivery device integrated with standard brain navigation and reportedly achieved >95% tumor-volume coverage. The company noted FDA Breakthrough Device Designation and acceptance into the FDA Total Product Life Cycle Advisory Program to accelerate development for GBM patients.
Alpha Tau (NASDAQ: DRTS) announced two abstracts from its pancreatic cancer pilot studies were accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (Jan 8-10, 2026) in San Francisco.
The abstracts report feasibility, safety and efficacy of endoscopic ultrasound-guided Alpha DaRT and inflammatory/immune marker dynamics after intratumoral Alpha DaRT from a recently completed Montreal pilot trial. Alpha Tau treated its first U.S. multi-center pancreatic cancer patient in September 2025; the U.S. trial plans to enroll up to 30 patients with recruitment expected to finish by the end of Q1 2026. The company emphasized the program targets a population where up to 87% of newly diagnosed patients are considered inoperable.